Triple negative breast cancer (TNBC) is the most lethal one for all types of breast cancer. Though radiotherapy is an efficient treatment, long-term survival rate of TNBC patients is still suboptimal. Hyprofractionated radiotherapy, an improved radiotherapy, has made an inspiring result in clinic. However, the mechanism underlying TNBC treated with hyprofractionated radiotherapy is not clear. Decorin (DCN) is a small poteoglycan of matrix which has an inhibitory effect on the breast cancer and is secreted by muscle under certain conditions. In this study, we demonstrated that peritumoral muscles secrete more DCN at higher dose irradiation than that at conventional irradiation dose in TNBC tumor-bearing mice. Thus, it indicates that DCN secreted from peritumoral muscle may be one of the reasons why hyprofractionated radiotherapy could inhibit the growth of TNBC more effectively. Moreover, we also indicated that the up-regulated DCN attenuated lung metastasis of TNBC. In conclusion, we demonstrated that hypofractionated radiation promotes the secretion of DCN in peritumoral muscle, thus enhancing the inhibitory effect on TNBC, which might help to optimize the strategy of radiotherapy for TNBC patients in the future.
Introduction
Breast cancer (BC), being the main cause of death from cancer in women, is indeed one of the most prevalent types of cancers worldwide [1] . Among all types of BC, triple negative breast cancer (TNBC), though only making up 15%-20%, is the most lethal one. TNBC is defined as breast cancer that does not overexpress estrogen receptor (ER), progesterone receptor (PR), and has no extraamplification of human epidermal growth factor receptor 2 (Her2) gene, which results in its resistance to hormone or trastuzumab treatment. Currently, besides surgery, common treatment options for TNBC patients are chemotherapy and radiotherapy. As one of the main treatment for TNBC patients, radiotherapy plays an important role in decreasing the local recurrence rate and further improves survival rate of patients. Moreover, postoperative radiotherapy is an effective way in the multidisciplinary treatment of high-risk breast cancer. However, current local control rate and overall survival of TNBC remain unsatisfied [2] , which makes the improvement of radiotherapy for TNBC patient an urgent task.
Nowadays, clinical researchers have concluded that the most efficient α/β ratio of breast cancer is around 3.5 Gy [3] , which is in favor of hyprofractionated radiotherapy [4] . Thus, hyprofractionated radiotherapy, such as intraoperative radiotherapy (IORT), has now been extensively investigated [5] [6] [7] [8] . Results showed that hyprofractionated radiation for TNBC patients got better outcome than those receiving conventional radiotherapy. This implicates that fractionation irradiation dose may be an independent prognostic factor in the prognosis of BC [8, 9] . Hence, the mechanism by which hyprofractionated radiotherapy has such advantages over conventional radiotherapy arouses our interest. Whether the hyperfractionated radiotherapy only enhances the radiophysical effect or stimulates the coordination of other anti-tumor factors is worth further study.
Decorin (DCN), a prototype member of the small leucine-rich proteoglycans family [10] , has been proved to be an antagonist to the progression of various types of tumors, such as lung cancer [11] , prostate cancer [12] , and BC [13] in the past 20 years. Involved in a number of biological processes such as inflammatory responses [14] , proliferation [15] , differentiation [16] , survival, and angiogenesis [17] , DCN is reported to suppress the endogenous production of the vascular endothelial growth factors and affect endothelial cell migration as well as tumor cell metastasis [18, 19] . In the last 10 years, DCN was proved to be released by skeletal muscles under certain conditions and termed as a 'myokine' which means that it plays a role in the interaction between muscles and other tissues. For example, DCN is considered to be involved in communication from skeletal muscle to bone and modulate bone metabolism [20] . In this study, we hypothesize that muscles around BC secret DCN during the period of TNBC patients receiving hyprofractional radiotherapy, which may help to inhibit the progress of TNBC.
In order to verify the above hypothesis, we modeled TNBC cell lines MDA-MB-231 on nude mice, and treated them with normal irradiation and hyprofractionated radiation. Then we analyzed the expression level of DCN in peritumoral muscles as well as the expressions of genes related to tumor progress and metastasis in the down-stream cascade of DCN in tumor tissues. The results indicated that, besides the direct destruction tumor tissue by irradiation, hyprofractionated radiation induced the expression of DCN in peritumoral muscle, whose anti-tumor effect further inhibited the progress and metastasis of TNBC.
Materials and Methods

Reagents and cell line
Antibodies used in this study were all from Cell Signaling Technologies (Danvers, USA). Reagents for western blot analysis (RIPA, PVDF membrane, transfer and running buffer) were all from Bio-Rad (Hercules, USA) unless otherwise stated. DMEM, FBS, 0.25% trypsin and PBS were all from GIBCO (Gaithersburg, USA), unless otherwise stated. Reagents for RNA extraction and quantitative RT-PCR are all from Invitrogen (Carlsbad, USA) unless otherwise stated. Recombined human DCN was purchased from R&D Systems (Minneapolis, USA). The TNBC cell line MDA-MB-231 was purchased from ATCC (Manassas, USA) and cultured in DMEM (high glucose), supplemented with 10% FBS and 1% penicillin/streptomycin, in a humidified atmosphere of 5% CO 2 at 37°C.
Establishment of the TNBC animal model
Female Balb/c mice (nu/nu, 6-8 weeks, weight 18-20 g) were purchased from Shanghai Laboratory Animal Research Center (Shanghai, China) and raised in a specific pathogen free (SPF) environment. MDA-MB-231 cells in logarithmic phase were suspended at a concentration of 3 × 10 7 cells/ml after trypsin digestion. About 50 μl cell suspension was injected into the back side of nude mice. The growth of the transplanted tumor was observed every 2 days. The diameter of the tumor reached 6-8 mm about 10 days after injection, which was ready for the subsequent radiotherapy.
Irradiation strategy
Before radiotherapy, mice were anesthetized by intraperitoneal injection of phenobarbital at a concentration of 1% and a dose of 1 ml per 10 g of body weight. The transplanted tumor was irradiated with Oncor Impression linear accelerator (Siemens, Berlin, Germany). The 6 MeV electron beam was chosen as irradiation energy based on the tumor depth. The mice were irradiated within 20 min after anesthesia. The source skin distance was 100 cm, and the dose rate was 3 Gy/min. The mice were divided into three groups. One is mold group, and the others were two separate single dose group. The total doses for the two different irradiation groups were 2 and 10 Gy, respectively.
Recording of tumor growth
The long diameter of tumor (a, mm) and the short diameter (b, mm) were measured every 2 days using a vernier caliper after irradiation treatment, and the tumor volume was calculated according to the formula:
.
Cell apoptosis analysis
Cells were isolated from TNBC xenograft treated with radiotherapy by enzymatic digestion. Then cells were washed three times with cold PBS and re-suspended in 100 μl binding buffer at a concentration of 1 × 10 6 cells/ml. Annexin V-FITC (5 μl) and PI (5 μl) (Dojindo Laboratories, Kumamoto, Japan) were added into the cell suspension and incubated at room temperature for 30 min. After addition of 400 μl binding buffer, the cell suspension was analyzed by flow cytometry using a Guava Flow Cytometer (Millipore, Billerica, USA).
Immunohistochemistry staining
Specimens of TNBC xenograft were fixed with 10% neutral buffered formaldehyde and were embedded in paraffin. Routine hematoxylin and eosin staining was performed on the sections for histopathologic evaluation. Tissue sections of 4-μm thicknesses were cut onto slides coated with 3-aminopropyltriethoxysilane. Anti-Ki-67 and anti-DCN (Santa Cruz Biotech, Santa Cruz, USA) antibodies were used to detect the expression of Ki-67 and DCN in mice tumors and peritumoral muscles according to the manufacturer's instructions.
RNA isolation and quantitative RT-PCR
Total RNA was extracted from tissues using the E.Z.N.A. ® Total RNA Kit IR6834-01 (OMEGA Bio-tek, Norcross, USA) according to the manufacturer's protocol, followed by reverse transcription using PrimerScript RT-PCR kit (TaKaRa Biotechnology, Dalian, China). Quantitative RT-PCR was performed using a SYBR MastMix kit (Roche, Mannheim, Germany) on an ABI 7900HT real-time instrument with software SDS version 2.3 (Thermo scientific, Waltham, USA). Primers used in this study are shown in Table 1 . The PCR were performed according to the instructions of SYBR MastMix. The relative expression was calculated using the 2 −ΔΔCt method, and eEF2 was used as an internal control.
Western blot analysis
The total proteins from the muscles or TNBC tissues were extracted using RIPA buffer with proteinase inhibitor. Prepared samples were then subject to 10% SDS-PAGE and electrophoretically transferred to a PVDF membrane. Membranes were blocked with 5% skim milk at room temperature for 1 h, followed by incubation with primary antibodies at 4°C for overnight. HRP-conjugated anti-rabbit or anti-mouse IgG was used as secondary antibody. Finally, blots were visualized using an enhanced chemiluminescence kit. Actin was used as the internal control.
Statistical analysis
Data were shown as the mean ± SD from triplicate measurements. Statistical analysis between two samples was performed using Student's t-test. Statistical comparisons of more than two groups were performed using two-way ANOVA. P < 0.05 was considered as significantly different.
Results
DCN was induced by hyprofractionated radiotherapy in peritumoral muscle
To mimic the process of TNBC patients receiving conventional and hyprofractionated radiotherapy, we set up nude mice models bared with TNBC cell line MBA-MD-231. The tumor-baring animals were irradiated with different regimens (0 Gy worked as a control, 2 Gy worked as a conventional group, 10 Gy worked as a hyprofractionated group). On Days 8 and 16 after irradiation, the peritumoral biceps femoris muscle and quadriceps femoris muscle, as well as their corresponding muscles on the control side in a same mouse were obtained, and RNA and protein extraction was performed (Fig. 1A) .
As showed in Fig. 1B , the volume of TNBC tumor on nude mice treated with high-dose irradiation (10 Gy) was smaller than those from mice treated with conventional-dose irradiation (2 Gy) and control, indicating that the nude mice model bared with TNBC cells receiving hyprofractionated radiation could mimic the process of TNBC patients receiving hyprofractionated radiotherapy. In order to find out a suitable check point for DCN analysis, a comparison of the mRNA levels of DCN in the peritumoral muscles and muscles on the control side was performed (Fig. 1C) . On Day 8 after irradiation, the mean fold change of DCN in peritumoral muscle in the mice of the control group was 1.007, compared with that of the control-side muscle, whereas the fold changes of DCN in peritumoral muscle of the 2 and 10 Gy group were 2.150 and 3.826, respectively, compared with those of their control-side muscles. There is a significant difference between each group. On Day 16 after irradiation, the fold changes of DCN in peritumoral muscle of the 0, 2, and 10 Gy group were 1.124, 1.614, and 1.461, respectively. However, there is no significant difference between each group. This means that the level of DCN in the peritumoral muscle is increased with the increase of the dosage of irradiation. Eight days of irradiation is better than 16 days of irradiation.
Then the mRNA and protein expression levels of DCN in the peritumoral muscle at 8 d were detected (Fig. 1D) . The results clearly showed that the expression of DCN was induced by highdose irradiation (10 Gy) in the quadriceps femoris muscle at both mRNA and protein levels. The mRNA level of DCN in the 10-Gy group was 1.925-fold higher than that in the control group. And the DCN protein level was also increased accordingly.
To validate our findings more directly, IHC of DCN was performed in both peritumoral muscles and xenograft tumor tissues from all groups. The expression of DCN was clearly up-regulated in the peritumoral muscles with increasing dosage of irradiation. In the xenograft tumor tissues, DCN was also more enriched in the extracellular matrix of the group receiving high dose of radiation than that of the control group (Fig. 1E) .
Hyprofractionated radiation induced DCN and inhibited the progression of TNBC xenografts
The above results demonstrated that hyprofractionated radiotherapy induced the expression of DCN in the peritumoral muscles. Hence, it raises the issue of how increased DCN attenuates the progression of TNBC xenograft. To address this issue, TNBC tumor tissues were collected from mice receiving radiotherapy of different dosages, and the receptor and down-stream interacting proteins and genes related to tumor cell growth and apoptosis were detected. It is known that membrane receptor EGFR is one of the receptors of DCN, whose activation would recruit down-stream interacting proteins and trigger the transcription of its target genes. Therefore, we analyzed the protein level of EGFR and its phosphorylation in the xenograft tissues. The results showed that the total protein level of EGFR was unchanged, but the phosphorylation of EGFR was highly upregulated in the 10 Gy group. Besides the down-stream interacting protein MYC, the transcription factor TFAP4 was also increased ( Fig. 2A) . Therefore, the down-stream target genes including Cyclindependent kinase inhibitor 1 A (CDNK1A) and programmed cell death 4 (PDCD4) were detected in xenograft tissues. The mRNA levels of CDNK1A and PDCD4 in the high dose group (10 Gy) were 2.275-and 1.637-fold higher than that from mice receiving no radiotherapy (Fig. 2B) . To further confirm whether their increased expression is triggered by DCN rather than by irradiation itself, we carried out an in vitro cell-based assay by adding recombinant DCN protein into MBA-MD-231 cell directly. As shown in Fig. 2C , DCN could obviously induce the expression of CDNK1A and PDCD4. To demonstrate the consequence of elevated DCN, we detected the level of Ki-67, a tumor growth marker, in TNBC tissues by immunohistochemistry. The results of Ki-67 staining verified the quantitative RT-PCR results of CDNK1A and PDCD4 (Fig. 2D) .
On the other hand, the tumor cell apoptosis induced by DCN confirmed the inhibitory effect of DCN on xenograft breast cancer tissues. The expression level of TNF-α in TNBC tumor tissues receiving high-dose radiotherapy (10 Gy) were 1.520-fold higher than that in tumor tissue receiving no radiotherapy. However, tumors receiving conventional irradiation dosage (2 Gy) showed no difference compared with the control (Fig. 2B) . In addition, TNF-α could indeed be induced by directly stimulating the MDA-MB-231 cells with recombinant DCN (Fig. 2C) . Accordingly, the apoptosis rate of TNBC tumor cells from mice receiving high-dose radiotherapy was 2.489-fold higher than that from mice receiving no radiotherapy (Fig. 2E) .
DCN attenuated the lung metastasis of TNBC xenograft with radiotherapy
DCN has been shown to play a role in tumor metastasis [18, 19] . We then explored whether peritumoral muscle-derived DCN is a mechanism underlying the inhibition of metastasis of TNBC patients receiving hyprofractionated radiotherapy. The down-stream proteins of DCN and the related proteins to tumor metastasis, i.e. HIF-1α and CTNNB, as well as the mRNA expression levels of two metastasis marker genes MMP2 and VEGFA were analyzed in the TNBC tissues from the nude mice. As shown in Fig. 3A , the protein levels of HIF-1α and CTNNB were decreased with increasing irradiation dose. The gene expression levels of MMP2 and VEGFA in TNBC tumor tissues receiving radiotherapy (10 Gy) were 31.9% and 57.8% of those in TNBC tumor tissues receiving no radiotherapy (Fig. 3B) . To further confirm the direct effect of DCN on tumor cells, an in vitro cell-based assay was also employed to test whether the decreased expression of MMP2 and VEGFA is caused by DCN (Fig. 3C) . The western blot analysis results of MDA-MB-231 clearly supported this hypothesis.
In order to detect the effect of DCN on TNBC cell metastasis, pulmonary metastasis of the mice receiving conventional and hyprofractionated radiotherapies were calculated. As shown in Fig. 3D , the metastatic niches were observed clearly (arrowed) and the total numbers of metastatic niches from three individuals were displayed. The results showed that hyprofractionated radiotherapy efficiently decreased the metastasis rates of TNBC (9 vs. 45 and 46).
Discussion
Despite of significant improvement in the treatments of breast cancer, outcome for TNBC remained suboptimal. With local-regional recurrences is approximated 10%-33%, and the 5-year overall survival rate is only 14% after the tri-modality therapy [6] [7] [8] [9] . TNBC cast a shadow on patients' lives. Current standstill outcome is due to the dose limitation of the normal organs at risk in the planning treatment volume. However, higher doses necessary for disease control are not safely delivered with conventional radiotherapy. Because of the relatively low α/β ratio of breast cancer (~3.5 Gy), hyprofractionated radiation may not significantly increase radiotherapy damage in late-response tissues comparing to conventional irradiation. Unconventional fractionation radiotherapies, such as moderate hyprofractionated radiation and extremely hyprofractionated radiation like IORT, have been investigated in clinic and the results are inspiring. Therefore, it is reasonable to pursue the radiobiological mechanism of hyprofractionated radiotherapy on TNBC, and further optimize the radiation dose.
Recently, studies have shown that the tumor microenvironment plays a crucial role in disease progression, including invasion and metastasis [21] [22] [23] . DCN, a matrix poteoglycan, is re-recognized for its potency against the progress and metastasis of breast cancer [24] [25] [26] [27] . Buraschi et al. [28, 29] reported that DCN modulated the tumor stroma and acted as a biological anti-tumorigenic factors in TNBC. Troup et al. [30] found that lower DCN levels were associated with larger tumor size, a shorter time to progress and poorer survival, and that lower DCN levels can even be an independent predictive factor for recurrence and survival. DCN is also identified to have prognostic value in breast cancer after neoadjuvant chemotherapy [31] . However, there is no study focusing on the expression of DCN in the tumor microenvironment of TNBC during radiotherapy.
In the present study, we analyzed the expression level of DCN in the peritumoral muscle of nude mice modeling TNBC xenografts receiving conventional (2 Gy) and hyprofractionated (10 Gy) radiotherapy and confirmed that the expression of DCN was induced in peritumoral muscles by hyprofractionated radiation compared with those receiving conventional irradiation or no irradiation (control group). However, the induction effect is limited, because we found that the trend of increased DCN expression was eliminated in 16 days after irradiation. According to our results, the induced DCN exerts its anti-tumor functions by triggering its down-stream key proteins, such as MYC and TFAP4, which in turn up-regulates the expressions of CDNK1A, PDCD4, and TNF-α. Basing on the current knowledge, CDNK1A inhibits the activity of CCDK2 or CDK4 complexes, and mediates p53-dependent cell cycle G1 phase arrest. PDCD4 inhibits the transcription of eTIF4A1 by preventing RNA binding, which attenuates the progress of TNBC xenografts. TNF-α is confirmed to be an apoptosis-inducing factor for TNBC [32] . Furthermore, we found that elevated DCN level also suppressed the lung metastasis of TNBC. HIF-1α and CTNNB which are believed to facilitate cancer metastasis were decreased under hyprofractionated radiation [33] , and metastasis marker genes MMP2 and VEGFA were also reduced, which is related to tumor metastasis. Taken together, our results indicate that the expressions of DCN induced by hyprofractionated radiotherapy in the peritumoral muscles not only inhibits the progress of TNBC xenograft, but also decreases its metastasis, which further inhibits the progress of TNBC, in addition to the direct destruction of TNBC tissues by irradiation (Fig. 4) .
To our knowledge, this is the first report to demonstrate the role of DCN in the treatment of TNBC during radiotherapy. However, our results are far from conclusive, and several important issues need to be further addressed. First, although we showed that DCN could be induced in the peritumoral muscle tissues via high-dose irradiation, and the proliferation and apoptosis of MDA-MB-231 cells could be inhibited and induced by elevated DCN, it is still not clear whether the elevated DCN in xenograft tissues are indeed secreted by peritumoral muscles. We will address this question in our future studies by using DCN conditional knockout mice. Second, we modeled MDA-MB-231 cells on the flank instead of the fat pad of nude mice. Though it is not the 'right' site of BC, flank injection is also acceptable in BC research [34, 35] . In this study, considering that the types of muscle tissues under breast and on flank are all striated muscles, we used flank injection to make the radiation easy. Hence, an improvement of mouse model will be carried out to make the microenvironment of xenograft closer to the real situation.
In summary, although our results from the TNBC-baring mice with radiotherapy are preliminary, the data of DCN-induced expression in peritumoral muscle is encouraging and open a new window for optimization of the strategy of radiotherapy for TNBC patients. Figure 4 . Schematic representation of the mechanism of DCN inhibiting TNBC progress and metastasis under hyprofractionated radiotherapy The activation of the expression of DCN plays vital roles in the inhibition of TNBC progress. In the present study, we demonstrated that DCN expression induced by hyprofractionated radiotherapy in the peritumoral muscles not only inhibits the tumor growth of TNBC by activating the EGFR/MYC/TFAP4 axis, but also blocks its metastasis by decreasing the expressions of HIF-1α and CTNNB.
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